{"entity":{"id":"sumanta-pal","kind":"person","name":"Sumanta K. Pal","aka":[],"tldr":"Led SWOG 1500, the first randomised trial to set a standard for papillary kidney cancer, and studies of the microbiome in RCC immunotherapy.","summary":"Sumanta Pal was principal investigator of SWOG PAPMET (S1500), which showed cabozantinib outperforms sunitinib in metastatic papillary renal cell carcinoma, the first practice-changing randomised trial in a non-clear-cell histology, and a lead investigator of COSMIC-313 and CONTACT-03. He led the randomised trial of the live bacterial product CBM588 with immunotherapy. He co-directs the kidney cancer programme at City of Hope.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pal%20SK%5BAuthor%5D%20renal%20cell"}],"tags":["rcc","swog","microbiome"],"related":[],"cancers":["rcc"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["nivolumab","ipilimumab","atezolizumab"],"companies":[],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":["cosmic-313","contact-03"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Co-Director, Kidney Cancer Program, City of Hope","institutionId":"city-of-hope","specialisms":["Renal cell carcinoma","Non-clear-cell histologies","Microbiome and immunotherapy","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pal%20SK%5BAuthor%5D%20renal%20cell"}],"papers":[{"title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma (SWOG 1500)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00152-5"},{"title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)00922-4"}]},"route":"/people/sumanta-pal/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"city-of-hope","kind":"institution","name":"City of Hope","route":"/institutions/city-of-hope/"}],"trial":[{"id":"contact-03","kind":"trial","name":"CONTACT-03","route":"/trials/contact-03/"},{"id":"cosmic-313","kind":"trial","name":"COSMIC-313","route":"/trials/cosmic-313/"},{"id":"papmet","kind":"trial","name":"PAPMET (SWOG S1500)","route":"/trials/papmet/"}]}}